Last reviewed · How we verify

NCT03417271

Short Pulse Width DBS in Parkinson's Disease

Completed Phase 2 Last updated 17 April 2019
What this trial tests

Phase 2 trial testing Deep brain stimulation in Parkinson's Disease in 16 participants. Completed in 24 October 2018.

Timeline
2 May 2018
Primary endpoint
24 October 2018
24 October 2018

Quick facts

Lead sponsorUniversity College, London
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment16
Start date2 May 2018
Primary completion24 October 2018
Estimated completion24 October 2018
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University College, London

Who can join

Eligibility, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this investigation is to explore the effect of reducing conventional pulse width of stimulation on known adverse effects of Subthalamic nucleus Deep Brain Stimulation (STN DBS) treatment such as; slurring of speech, gait impairment, and unsteadiness. This investigation is designed such that each of 16 patients (who have all had chronically implanted DBS systems), will be assessed using conventional (DBS-60µs) and short (DBS-30µs) pulse width DBS, in a randomised order.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?
    Bayram E, Batzu L, Tilley B, Gandhi R, et al · · 2023 · cited 13× · PMID 37031010 · DOI 10.1016/j.parkreldis.2023.105385

Verify or expand the search:

Other trials of Deep brain stimulation

Trials testing the same drug.

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

Other University College, London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03417271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing